The effect of drug therapy and cetuximab on the mutational status of the KRAS gene in patients with squamous cell carcinoma of the tongue and oral floor mucosa
- Authors: Lyanova A.A1, Vladimirova L.Y.1, Kutilin D.S1, Abramova N.A1, Popova I.L1, Tikhanovskaya N.M1, Teplyakova M.A1, Novoselova K.A1, Myagkova V.S1, Alieva F.V1, Ryadinskaya L.A1
-
Affiliations:
- National Medical Research Center for Oncology
- Issue: Vol 28, No 7 (2021)
- Pages: 68-77
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313181
- DOI: https://doi.org/10.18565/pharmateca.2021.7.68-76
- ID: 313181
Cite item
Abstract
Full Text
About the authors
A. A Lyanova
National Medical Research Center for Oncology
Email: blackswan-11@mail.ru
Rostov-on-Don, Russia
L. Yu Vladimirova
National Medical Research Center for OncologyRostov-on-Don, Russia
D. S Kutilin
National Medical Research Center for OncologyRostov-on-Don, Russia
N. A Abramova
National Medical Research Center for OncologyRostov-on-Don, Russia
I. L Popova
National Medical Research Center for OncologyRostov-on-Don, Russia
N. M Tikhanovskaya
National Medical Research Center for OncologyRostov-on-Don, Russia
M. A Teplyakova
National Medical Research Center for OncologyRostov-on-Don, Russia
K. A Novoselova
National Medical Research Center for OncologyRostov-on-Don, Russia
V. S Myagkova
National Medical Research Center for OncologyRostov-on-Don, Russia
F. V Alieva
National Medical Research Center for OncologyRostov-on-Don, Russia
L. A Ryadinskaya
National Medical Research Center for OncologyRostov-on-Don, Russia
References
- Rodrigues R.M., Bernardo V.G., Da Silva S.D., et al. How pathological criteria can impact prognosis of tongue and floor of the mouth squamous cell carcinoma. J Appl OralSci. 2019;28:e20190198. doi: 10.1590/1678-7757-2019-0198. PMID: 31800876; PMCID: PMC6886392.
- Ord R.A. Surgical management of the N0 neck in early stage T1-2 oral cancer; a personal perspective of early and late impalpable disease. Oral Maxillofac Surg. 2012;16(2):181-88. doi: 10.1007/s10006-012-0325-x. PMID: 22581159.
- Ferlay J., Colombet M., Soerjomataram I., et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. doi: 10.1002/ijc.31937. PMID: 30350310.
- Wang W.-Y., Chien Y.-C., Wong Y.-K, et al. Effects of kras mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Accepted 22 February 2011 Published on-line 17 June 2011 in Wiley On-line Library (wileyonlinelibrary.com). Doi: 10.1002/ hed.21792.
- Liu P, Wang Y., Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm. Sin. B. 2019;9(5):871-79. Doi: 10.1016/j. apsb.2019.03.002. PMID: 31649840; PMCID: PMC6804475.
- Huang M., Shen A., Ding J., Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci. 2014;35(1):41-50. Doi: 10.1016/j. tips.2013.11.004. PMID: 24361003.
- Pylayeva-Gupta Y, Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761-74. doi: 10.1038/nrc3106. PMID: 21993244; PMCID: PMC3632399.
- Young A., Lou D., McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013;3(1):112-23. doi: 10.1158/2159-8290.CD-12-0231. PMID: 23103856.
- Владимирова Л.Ю., Льянова А.А., Франциянц Е.М. и др. Молекулярные механизмы резистентности к терапии моноклональными антителами у больных плоскоклеточным раком языка и слизистой дна полости рта. Злокачественные опухоли. 2018;8(4):13-25.
- Oellerich M., Schutz E., Beck J., et al. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy. Ther. Drug Monit. 2019;41(2):115-20. doi: 10.1097/FTD.0000000000000566. PMID: 30883505.
- Льянова А.А. Изучение резистентности к анти-EGFR моноклональному антителу у больных плоскоклеточным раком языка и слизистой оболочки дна полости рта. Дисс. канд. мед. наук. Ростов-на-Дону, 2020.
- Льянова А.А., Владимирова Л.Ю., Франциянц Е.М. и др. Молекулярные основы современной таргетной терапии плоскоклеточного рака языка и слизистой дна полости рта моноклональными антителами. Злокачественные опухоли. 2017;7:77-83
- Lin F., Yao L., Xiao J., et al. MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma Onco Targets and Therapy. Department of Orthodontics, Department of Pedodontics, Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, People's Republic of China. doi: 10.2147/OTT.S67624.
- Alorabi M, Shonka N.A., Ganti A.K. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role? Crit Rev Oncol Hematol. 2016;99:170-79. doi: 10.1016/j.critrevonc. 2015.12.006. PMID: 26797287.
- Льянова А.А., ВладимироваЛ.Ю., Ульянова Е.П. и др. Изучение экспрессии EGFR в ткани опухоли у больных местно-распространенным раком полости рта при терапии цетуксимабом. Медицинский совет. 2020;9:182-89.
- Boeckx C., Weyn C., Vanden Bempt I., et al. Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. BMC. Res Notes. 2014;7:337. doi: 10.1186/1756-0500-7-337. PMID: 24899223; PMCID: PMC4067106.
- O'Keefe R.A., Bhola N.E., Lee D.S.,etal. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS One. 2020;15(1):e0227261. doi: 10.1371/journal. pone.0227261. PMID: 31914141; PMCID: PMC6948745.
- QX200™ Droplet Reader and QuantaSoft™ Software Instruction Manual Catalog #186-4001, 186-4003.
- Manual Тест cobas® EGFR Mutation Test v2.
- QX200™ Droplet Generator Instruction Manual Catalog #186-4002.
- Lyanova A.A., Vladimirova L.Yu., Engibaryan M.A., et al. The KRAS mutation status and resistance to cetuximab in patients with squamous cell carcinoma of oral cavity. J Clin Oncol. 2020;38(Suppl, abstr.):e15514. Doi: 10.1200/ JCO.2020.38.15_suppl.e15514.
- Volckmar A.L., Sultmann H., Riediger A., et al. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. Gen Chrom Cancer. 2018;57(3):123-39. doi: 10.1002/gcc.22517. PMID: 29205637.
- Ranucci R. Cell-Free DNA: Applications in Different Diseases. Meth. Mol. Biol. 2019;1909:3-12. doi: 10.1007/978-1-4939-8973-7 1. PMID: 30580419.
- Lievre A, Laurent-Puig P Genetics: Predictive value of KRAS mutations in chemoresistant CRC. Nat Rev Clin Oncol. 2009;6(6):306-7. doi: 10.1038/nrclinonc.2009.69. PMID: 19483733.
- Wheeler D.L., Dunn E.F, Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7(9):493-507. Doi: 10.1038/ nrclinonc.2010.97. PMID: 20551942; PMCID: PMC2929287.
- Braig F, Voigtlaender M., Schieferdecker A, et al. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget. 2016;7(28):42988-95. Doi: 10.18632/ oncotarget.8943. PMID: 271 19512; PMCID: PMC5190002.